
Opinion|Videos|December 11, 2024
Drug Classes Available to Treat Patients With High Blood Pressure
Key Takeaways
- Antihypertensive drug classes include diuretics, beta-blockers, ACE inhibitors, ARBs, calcium channel blockers, and alpha-blockers, each with distinct mechanisms of action targeting blood pressure regulation.
- Diuretics reduce blood volume, beta-blockers decrease heart rate, ACE inhibitors and ARBs inhibit the renin-angiotensin-aldosterone system, and calcium channel blockers relax blood vessels.
Panelists discuss how antihypertensive treatment encompasses multiple drug classes with distinct mechanisms of action, alongside lifestyle modifications such as dietary changes and exercise, providing a comprehensive approach to blood pressure management.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- There are numerous traditional drug classes available to treat patients with high blood pressure.
- What are the main antihypertensive drug classes and what are their mechanisms of action?
- What are some nonpharmacological approaches for treating hypertension?
Advertisement
Related to this article

Ankeet Bhatt, MD, MBA, ScM, explains how prediction markets could threaten clinical trial integrity by undermining participant retention and trust.

Diana Isaacs, PharmD, and Natalie Bellini, DNP, review OPTIMAL-DIABETES, SYNCHRONIZE-CVOT, and ATTAIN-OSA data from AHA 2026.

Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss tubeless Mobi's FDA clearance, CVS Caremark's CGM formulary shift, and a transmitter-free implant.

Aficamten's label now includes MAPLE-HCM data, in which aficamten monotherapy improved peak VO2 by 2.3 mL/kg/min more than metoprolol at 24 weeks.

Dexmedetomidine sublingual film is the first FDA-approved at-home option for acute agitation, based on the phase 3 SERENITY at-home trial.

Hiddo Heerspink, PharmD, PhD, joins Brendon Neuen, MBBS, PhD, and Shikha Wadhwani, MD, MS, to unpack finerenone’s FIND-CKD data in FSGS.

Lesley Inker, MD, MS, joins Brendon Neuen, MBBS, PhD, to unpack GFR slope and hierarchical composite endpoints in glomerular disease trials.
Advertisement
Advertisement
Trending on HCPLive
1
ABCs in Dermatology: Rethinking Corticosteroid Stewardship in Chronic Hand Eczema
2
FDA Updates Aficamten Label With MAPLE-HCM Data in Obstructive HCM
3
Early Dupilumab in Pediatric EoE Tied to Lower Incident Asthma
4
Asundexian’s FDA Approval Opens Doors for Future Antithrombotic Therapies
5

